Metrics as of 10/16/2026, 08:54 AM (Berlin time), refresh in progress.
Sol-Gel Technologies Stock
Sol-Gel Technologies Ltd.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- CEO
- Moshe Arkin
- Employees
- 28
- Market cap
- $225 M
- IPO
- 01/02/2018
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities…
Sol-Gel Technologies stock: price history
1D
-1.2%
1W
-2.3%
1M
+6.7%
6M
-8.8%
YTD
+63.0%
1Y
+64.5%
2Y
+925.4%
5Y
-26.3%
10Y
–
Next earnings date
Next earnings date
19/11/2026 (in 33 days)
Volatility around earnings
~10% weaker price swings than usual
Ask the agents about Sol-Gel Technologies
Analyst assessment of Sol-Gel Technologies
PRICE TARGET LOW
US$110.00
CONSENSUS
US$110.00
MEDIAN
US$110.00
PRICE TARGET HIGH
US$110.00
0
STRONG BUY
5
BUY
1
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 20/07/2026
Sol-Gel Technologies stock metrics
P/E
-12.18
P/B
4.67
EV/EBITDA
-12.03
RETURN ON EQUITY
-7.7%
NET MARGIN
-622.8%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
26.1%
FLOAT SHARES
854,350
AVG. DAILY VOLUME (30D)
43,438
Insider transactions (SEC)
Opaleye Management Inc.
Opaleye Management Inc.
Opaleye Management Inc.
Opaleye Management Inc.
Opaleye Management Inc.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Sol-Gel Technologies stock
What does Sol-Gel Technologies do?
Sol-Gel Technologies Ltd. is a company in the Healthcare sector, Biotechnology industry, headquartered in Israel.
The CEO is Moshe Arkin, the company employs around 28 people.
The IPO was on 01/02/2018; the stock trades on NASDAQ under the ticker SLGL.
What do analysts say about Sol-Gel Technologies stock?
6 analysts rate the stock, the consensus is Buy (as of 20/07/2026).
The average price target is US$110.00, ranging from US$110.00 to US$110.00, with a median of US$110.00.
This is an external assessment, not a statement by Market Jury.
When does Sol-Gel Technologies report next?
The next earnings date is 19/11/2026.
Around past earnings, price swings were roughly -10% stronger than usual.
Does Sol-Gel Technologies pay a dividend?
No, Sol-Gel Technologies currently does not pay a dividend.
Which stocks are comparable to Sol-Gel Technologies?
Comparable stocks include Alpha Tau Medical, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Sol-Gel Technologies stock analyzed?
Clicking "Analyze stock" lets five strategies assess Sol-Gel Technologies against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.